Laryngopharyngeal reflux: clinical significance, modern approaches to diagnosis and treatment
https://doi.org/10.21518/2079-701X-2019-3-8-16
Abstract
Gastroesophageal reflux disease (GERD) is one of the most common pathologies in modern clinical practice. Laryngopharyngeal reflux (LPR) is considered to be an extraesophageal manifestation of GERD and is characterized by retrograde ingestion of gastric content into the larynx and pharynx, leading to recurrent otolaryngological symptoms. Classical manifestations of LPR are hoarseness, perspiration, dryness and feeling of lump in the throat, coughing. There is no «gold standard» for the diagnosis of LPR. At the same time, several instrumental methods are used in clinical practice to verify the diagnosis: laryngoscopy and EGDS are the most common, and in some cases - 24-hour pH-metry and impedancemetry. In the case of an established diagnosis of LPR, it is recommended to use a standard dosage of PPI twice a day for 3–6 months.
About the Authors
I. V. Maev
Federal State Budgetary Educational Institution of the Higher Education «Moscow State University of Medicine and Dentistry named after A.I. Yevdokimov» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Dr. of Sci. (Med), Professor, Academician of the Russian Academy of Sciences, Head of the Department of Propaedeutics of Internal Diseases and Gastroenterology, Honored Doctor of the Russian Federation, Honored Scientist of the Russian Federation,
127473, Moscow, 20, Delegateskaya St.
J. V. Selskaya
European Medical Center Joint Stock Company
Russian Federation
Russian Federation
Candidate of Medical Sciences, Head of the Clinic of Otorhinolaryngology, Head and Neck Surgery of the European Medical Center,
35, Shchepkina St., Moscow, 129090
D. N. Andreev
Federal State Budgetary Educational Institution of the Higher Education «Moscow State University of Medicine and Dentistry named after A.I. Yevdokimov» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Candidate of Medical Sciences, Associate Professor of the Department of Propaedeutics of Internal Diseases and Gastroenterology, Researcher of the Laboratory of Functional Research Methods in Gastroenterology,
127473, Moscow, 20, Delegateskaya St.
D. T. Dicheva
Federal State Budgetary Educational Institution of the Higher Education «Moscow State University of Medicine and Dentistry named after A.I. Yevdokimov» of the Ministry of Healthcare of the Russian Federation;
European Medical Center Joint Stock Company
Russian Federation
Russian Federation
Candidate of Medical Sciences, Associate Professor of the Department of Propaedeutics of Internal Diseases and Gastroenterology, 127473, Moscow, 20, Delegateskaya St.;
gastroenterologist, 35, Shchepkina St., Moscow, 129090
Z. N. Bogolepova
European Medical Center Joint Stock Company
Russian Federation
Russian Federation
otorhinolaryngologist, phoniatrist,
35, Shchepkina St., Moscow, 129090
E. I. Kuznetsova
Federal State Budgetary Educational Institution of the Higher Education «Moscow State University of Medicine and Dentistry named after A.I. Yevdokimov» of the Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
postgraduate student of the Department of Propaedeutics of Internal Diseases and Gastroenterology,
127473, Moscow, 20, Delegateskaya St.
References
1. Ivashkin V.T., Maev I.V., Trukhmanov A.S., Baranskaya E.K., Dronova O.B., Zairatyants O.V., Sayfutdinov R.G., Sheptulin A.A., Lapina T.L., Pirogov S.S., Kucheryavy Yu.A., Storonova O.A, Andreev D.N. Clinical recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of gastroesophageal reflux disease. Rus journ of gastroenterol gastroenterol hepatol coloproctol [Ros zhurn gastrojenterol gepatol koloproktol.] 2017;27(4):75-95. (In Russ.)
2. Maev I.V., Burkov S.G., Yureniev G.L. Gastroesophageal reflux disease and associated pathology. М., 2014. (In Russ.)
3. Vakil N., van Zanten S.V., Kahrilas P., Dent J., Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900-1920.
4. Campagnolo A.M., Priston J., Thoen R.H., Medeiros T., Assunção A.R. Laryngopharyngeal reflux: diagnosis, treatment, and latest research. Int Arch Otorhinolaryngol. 2014 Apr;18(2):184-191.
5. Ford C.N. Evaluation and management of laryngopharyngeal reflux. JAMA. 2005;294: 1534–1540.
6. Asaoka D., Nagahara A., Matsumoto K., Hojo M., Watanabe S. Current perspectives on reflux laryngitis. Clin J Gastroenterol. 2014;7(6):471-475.
7. Zhang D., Zhou J., Chen B., Zhou L., Tao L. Gastroesophageal reflux and carcinoma of larynx or pharynx: a meta-analysis. Acta Otolaryngol. 2014 Oct;134(10):982-989.
8. El-Serag H., Sweet S., Winchester C., Dent J. Update on the epidemiology of gastrooesophageal reflux disease: a systematic review. Gut. 2014;63:871–880.
9. Dent J., El-Serag H.B., Wallander M.A. et al. Epidemiology of gastro-oesoрhageal reflux disease: a systematic review. Gut. 2005;54: 710–717.
10. El-Serag H.B. Time trends of gastroesoрhageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007;5:17–26.
11. Pohl H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146.
12. Altman K.W., SteрНens R.M., Lyttle C.S., Weiss K.B. Changing impact of gastroesoрhageal reflux in medical and otolaryngology practice. Laryngoscope. 2005;115:1145–1153.
13. Fraser A.G. Review article: gastro-oesophageal reflux and laryngeal symptoms. Aliment Pharmacol Ther. 1994;8:265–272.
14. Koufman J.A. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 1991;101:1–78.
15. Ing A.J., Ngu M.C., Breslin A.B. Pathogenesis of chronic persistent cough associated with gastroesophageal reflux. Am J Respir Crit Care Med. 1994;149:160–167.
16. Adhami T., Goldblum J.R., Richter J.E., Vaezi M.F. The role of gastric and duodenal agents in laryngeal injury: an experimental canine model. Am J Gastroenterol. 2004;99:2098–2106.
17. Galli J., Calo L., Agostino S. et al. Cammarota G. Bile reflux as possible risk factor in laryngoрharyngeal inflammatory and neoplastic lesions. Acta Otorhinolaryngol Ital. 2003;23:377–382.
18. Johnston N., Knight J., Dettmar P.W., Lively M.O., Koufman J. Pepsin and carbonic anhydrase isoenzyme markers for laryngoрНaryngeal reflux disease. Laryngoscope. 2004;114:2129–2134.
19. Johnston N., Wells C.W., Blumin J.H., Toohill R.J., Merati A.L. Receptormediated uptake of pepsin by laryngeal epithelial cells. Ann OtolRhinol Laryngol. 2007;116:934–938.
20. Koufman J.A. Low-acid diet for recalcitrant laryngoрНaryngeal reflux: therapeutic benefits and their implications. Ann Otol Rhinol Laryngol. 2011;120:281–287.
21. Johnston N., Dettmar P.W., Lively M.O. et al. Effect of pepsin on laryngeal stress protein (Sep70, Sep53, and Hsp70) response: role in laryngoрНaryngeal reflux disease. Ann Otol Rhinol Laryngol. 2006;115:47–58.
22. Loughlin C.J., Koufman J.A. Paroxysmal laryngospasm secondary to gastroesoр. Нageal reflux. Laryngoscope. 1996;106:1502–1505.
23. Sasaki C.T., Suzuki M. Laryngeal spasm: a neuroрНysiologic redefinition. Ann Otol Rhinol Laryngol. 1977;86:150–157.
24. Bove M.J., Rosen C. Diagnosis and management of laryngoрНaryngeal reflux disease. Curr Opin Otolaryngol Head Neck Surg. 2006;14:116–123.
25. Belafsky P.C., Postma G.N., Koufman J.A. Validity and reliability of the reflux symptom index (RSI). J Voice. 2002;16:274–277.
26. Branski R.C., Bhattacharyya N., Shapiro J. The reliability of the assessment of endoscopic laryngeal findings associated with laryngoрНaryngeal reflux disease. Laryngoscope. 2002;112:1019–1024.
27. Belafsky P.C., Postma G.N., Koufman J.A. The validity and reliability of the reflux finding score (RFS). Laryngoscope. 2001;111:1313–1317.
28. Park W., Hicks D.M., Khandwala F. et al. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. Laryngoscope. 2005;115:1230–1238.
29. Maev I.V., Barkalova E.V., Ovsepyan M.A., Kucheryavy Yu.A., Andreev D.N. Possibilities of high resolution pH-impedancemetry and manometry in the management of patients with refractory gastroesophageal reflux disease. Therapeutic archive [Terapevticheskij arhiv]. 2017;89(2):76-83. (In Russ.)
30. Noordzij J.P., Khidr A., Desper E., Meek R.B., Reibel J.F., Levine P.A. Correlation of pH probemeasured laryngopharyngeal reflux with symptoms and signs of reflux laryngitis. Laryngoscope. 2002;112:2192–2195.
31. Vaezi M.F., Hicks D.M., Abelson T.I., Richter J.E. Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause and effect association. Clin Gastroenterol Hepatol. 2003;1:333–344.
32. Yuksel E.S., Slaughter J.C., Mukhtar N., Ochieng M., Sun G., Goutte M., Muddana S. Gaelyn Garrett C., Vaezi M.F. An oropharyngeal pH monitoring device to evaluate patients with chronic laryngitis. Neurogastroenterol Motil. 2013;25:e315–323.
33. Ayazi S., Lipham J.C., Hagen J.A., Tang A.L., Zehetner J., Leers J.M., Oezcelik A., Abate E., Banki F., DeMeester S.R., DeMeester T.R. A new technique for measurement of pharyngeal pH: normal values and discriminating pH threshold. J Gastrointest Surg. 2009;13:1422–1429.
34. Reimer C., Bytzer P. Management of laryngopharyngeal reflux with proton pump inhibitors. Ther Clin Risk Manag. 2008;4:225–233.
35. Altman K.W., Prufer N., Vaezi M.F. The challenge of protocols for reflux disease: a review and development of a critical pathway. Otolaryngol Head Neck Surg. 2011;145:7–14.
36. Maev I.V., Andreev D.N., Dicheva D.T. Gastroesophageal reflux disease: from pathogenesis to therapeutic aspects. Consillium medicum. 2013;15(8):30-34. (In Russ.)
37. Maev I.V., Samsonov A.A., Dicheva D.T., Andreev D.N., Andreev N.G., Bouragina T.A. Actual approaches to diet therapy for diseases of the upper gastrointestinal tract. Medical bulletin of the Ministry of Internal Affairs [Medicinskij vestnik MVD. 2012;4:57–61.] (In Russ.)
38. Steward D.L., Wilson K.M., Kelly D.H., Patil M.S., Schwartzbauer H.R., Long J.D., Welge J.A. Proton pump inhibitor therapy for chronic laryngoрНaryngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg. 2004; 131: 342–350.
39. Koufman J.A. Low-acid diet for recalcitrant laryngoрНaryngeal reflux: therapeutic benefits and their implications. Ann Otol Rhinol Laryngol. 2011;120:281–287.
40. Federal Guidelines on the Use of Medicines (formular system). Volume XVIII. M.: Vidox, 2017. (In Russ.)
41. Liu C., Wang H., Liu K. Meta-analysis of the efficacy of proton pump inhibitors for the symptoms of laryngopharyngeal reflux. Braz J Med Biol Res. 2016 Jul 4;49(7). pii: S0100-879X2016000700704.
42. Wei C. A meta-analysis for the role of proton pump inhibitor therapy in patients with laryngopharyngeal reflux. Eur Arch Otorhinolaryngol. 2016 Nov;273(11):3795-3801.
43. Yang Y., Wu H., Zhou J. Efficacy of acid suppression therapy in gastroesophageal reflux disease-related chronic laryngitis. Medicine (Baltimore). 2016 Oct;95(40):e4868.
44. Bove M.J., Rosen C. Diagnosis and management of laryngopharyngeal reflux disease. Curr Opin Otolaryngol Head Neck Surg. 2006;14:116–123.
45. Andreev D.N., Kucheryavy Yu.A. Pros pects of treatment of gastroesophageal reflux disease. Cons. Med. Gastroenterology. [Cons. Med. Gastrojenterologija.] 2013;2:9-14. (In Russ.)
46. Maev I.V., Samsonov A.A., Andreev D.N. Prospects of application of proton pump inhibitor of new generation - dexlansoprazole in therapy of gastroesophageal reflux disease. Pharmacy [Farmateka]. 2015;2:6-11. (In Russ.)
47. Mayer M.D., Vakily M., Witt G., Mulford D.J. The Pharmacokinetics of TAK-390MR 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and Lansoprazole 60 mg: a retrospective analysis. Gastroenterology. 2008;134(Suppl. 1):A-176.
48. Metz D.C., Vakily M., Dixit T., Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment Pharmacol Ther. 2009;29(9):928-937.
49. Vakily M., Zhang W., Wu J., Atkinson S., Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009;25:627– 638.
50. Sharma P., Shaheen N.J., Perez M.C. et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation–results from two randomized controlled studies. Aliment Pharmacol Ther. 2009;29:731–741.
51. Liang C.M., Kuo M.T., Hsu P.I., Kuo C.H., Tai W.C., Yang S.C., Wu K.L., Wang H.M., Yao C.C., Tsai C.E., Wang Y.K., Wang J.W., Huang C.F., Wu D.C., Chuah S.K; Taiwan Acid-Related Disease Study Group. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease. World J Gastroenterol. 2017 Dec 21;23(47):8395-8404.
52. Peura D.A., Pilmer B., Hunt B., Mody R., Perez M.C. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. Aliment Pharmacol Ther. 2013;37(8):810-818.
53. Fass R., Chey W.D., Zakko S.F. et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2009;29(12):1261-1272.
54. Boulanger L., Mody R., Bao Y. et al. Does the Dosing Frequency of Proton Pump Inhibitors (PPIs) Affect Medication Adherence Among Patients Diagnosed with Gastroesophageal Reflux Disease (GERD)? Gastroenterology. 2008;134(4 Suppl. 1):A321-322.
55. Kucheriavy Yu.A., Andreev D.N. Prospects for the treatment of patients with acid-dependent diseases. Klin. Perspektivy Gastroenterol., Gepatol. 2014;2:15-24. (In Russ).
56. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010 Sep;32(6):720-37. doi: 10.1111/j.1365-2036.2010.04406.x.
57. Roman S, Mion F. Refractory GERD, beyond proton pump inhibitors. Curr Opin Pharmacol. 2018 Dec;43:99-103. doi: 10.1016/j.coph.2018.09.001. Epub 2018 Sep 18.
58. David C. Metz , Betsy L. Pilmer, Cong Han and M. Claudia Perez. Withdrawing PPI Therapy After Healing Esophagitis Does Not Worsen Symptoms or Cause Persistent Hypergastrinemia: Analysis of Dexlansoprazole MR Clinical Trial Data Am J Gastroenterol 2011; 106:1953– 1960; doi: 10.1038/ajg.2011.220; published online 16 August 2011.
59. Fass R, Inadomi J, Han C, Mody R, O’Neil J, Perez MC. Maintenance of heartburn relief after stepdown from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol. 2012 Mar;10(3):247-53. doi: 10.1016/j.cgh.2011.11.021.
60. Lee RD, et al. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibilty with a Dual Delayed Response proton pump inhibitor. Aliment Pharmacol Ther 2010;31:1001–11.
61. Zhang W, Wu J, Atkinson S. Pharmacokinetics, pharmacodynamics, and safety evaluation of a single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified-release TAK-390 (TAK390MR) and 30 mg oral doses of lansoprazole in healthy subjects. Gastroenterology 2007; 132(suppl 52): A487 (abstract).
62. Kukulka M, et al. Comparator pH study to evaluate the single dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mg Clin Exp Gastroenterol 2011;4:213-20
63. Ratnasingam D, Irvine T, Thompson SK, Watson DI. Laparoscopic antireflux surgery in patients with throat symptoms: a word of caution. World J Surg 2011;35:342–348
64. Deveney CW, Benner K, Cohen J. Gastroesophageal reflux and laryngeal disease. Arch Surg. 1993;128:1021–5.
Review
For citations:
Maev IV, Selskaya JV, Andreev DN, Dicheva DT, Bogolepova ZN, Kuznetsova EI. Laryngopharyngeal reflux: clinical significance, modern approaches to diagnosis and treatment. Meditsinskiy sovet = Medical Council. 2019;(3):8-16. (In Russ.) https://doi.org/10.21518/2079-701X-2019-3-8-16
Views:
3581
Email this article 